[go: up one dir, main page]

Feng et al., 2020 - Google Patents

Virtual screening and optimization of novel mTOR inhibitors for radiosensitization of hepatocellular carcinoma

Feng et al., 2020

View PDF
Document ID
4193535424418590307
Author
Feng Y
Gu S
Chen Y
Gao X
Ren Y
Chen J
Lu Y
Zhang H
Cao S
Publication year
Publication venue
Drug Design, Development and Therapy

External Links

Snippet

Background Radiotherapy has an ameliorative effect on a wide variety of tumors, but hepatocellular carcinoma (HCC) is insensitive to this treatment. Overactivated mammalian target of rapamycin (mTOR) plays an important part in the resistance of HCC to radiotherapy; …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase

Similar Documents

Publication Publication Date Title
Ramsay et al. A perspective on multi-target drug discovery and design for complex diseases
Li et al. Development and characterization of a Wee1 kinase degrader
Feng et al. Virtual screening and optimization of novel mTOR inhibitors for radiosensitization of hepatocellular carcinoma
Türe et al. Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids
Yaguchi et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor
Carbone et al. Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification
Gabr et al. New series of benzothiazole and pyrimido [2, 1-b] benzothiazole derivatives: synthesis, antitumor activity, EGFR tyrosine kinase inhibitory activity and molecular modeling studies
Sivakumaren et al. Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
KR20120063515A (en) Pi3 kinase inhibitors and uses thereof
Hou et al. Design, synthesis and biological evaluation of novel 7-amino-[1, 2, 4] triazolo [4, 3-f] pteridinone, and 7-aminotetrazolo [1, 5-f] pteridinone derivative as potent antitumor agents
Jester et al. Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen
Jin et al. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno [2, 3-d] pyrimidine scaffold
Xie et al. Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1)
Bergant et al. Structure-guided optimization of 4, 6-substituted-1, 3, 5-triazin-2 (1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα
Yin et al. 6, 7-Dihydrobenzo [f] benzo [4, 5] imidazo [1, 2-d][1, 4] oxazepine derivatives as selective inhibitors of PI3Kα
Elkamhawy et al. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: A decade review (2011–2021) focussing on structure–activity relationship (SAR) and docking insights
Hossen et al. PDK1 disruptors and modulators: a patent review
Peyressatre et al. Identification of quinazolinone analogs targeting CDK5 kinase activity and glioblastoma cell proliferation
Barile et al. PDK1 inhibitors
Tan et al. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors
Murthy et al. [1, 2, 4] Triazolo [3, 4-b] benzothiazole scaffold as versatile nicotinamide mimic allowing nanomolar inhibition of different PARP enzymes
Platzer et al. Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II
Lough et al. Triazolo [4, 5-d] pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells
Sarkar et al. Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition
Ghorab et al. Design, synthesis and molecular modeling study of certain quinazolinone derivatives targeting poly (ADP-ribose) polymerase 1 (PARP-1) enzyme as anti-breast cancer and radio-sensitizers